Skip to main content
. 2020 Sep 19;11(2):420–433. doi: 10.1016/j.apsb.2020.09.008

Figure 2.

Figure 2

JZA02 promoted apoptosis and enhanced the maturation and activity of dendritic cells. (A) JZA02 induced apoptosis of HCT-116 and SW620. HCT-116 and SW620 cells were incubated with 100 nmol/L JZA01, 100 nmol/L JZA02, or 200 nmol/L IFNα for 48 h and analyzed by flow cytometry following staining with Annexin V-FITC and PI. (B) Annexin V positive cells in Q2 and Q3 were considered apoptotic and are shown quantitatively as the mean ± SD, n = 3; ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. (C) Flow cytometry assay of the expression of MHC class I of HCT-116 and SW620 cells under different treatments (JZA01 100 nmol/L, JZA02 100 nmol/L, or IFNα 200 nmol/L) for 48 h. Immature dendritic cells were isolated from non-activated hPBMCs and incubated under different treatments for 72 h. The expressions of CD80 and CD86 were detected by flow cytometry assay. The red, green, orange, and blue lines represent PBS treatment, JZA02 treatment, IFNα treatment, and JZA01 treatment, respectively. (D) The results in (C) are presented as the mean ± SD, n = 3; ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.